SEC Form 4 · accession 0000886163-18-000154
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles S Berkman
Officer — SVP, Gen. Counsel & Secretary
Period of report
Oct 24, 2018
Accepted (ET)
Oct 25, 2018 · 5:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 24, 2018 | M | 2,688 | $14.47 | A | 32,451 | D | |
| Common Stock | Oct 24, 2018 | M | 1,212 | $21.92 | A | 33,663 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $21.92 | Oct 24, 2018 | M | 1,212 | D | — | Feb 15, 2023 | Common Stock | 1,212 | 3,644 | D |
| Incentive Stock Option (right to buy)F2 | $14.47 | Oct 24, 2018 | M | 2,688 | D | — | Feb 9, 2022 | Common Stock | 2,688 | 0 | D |
Explanation of responses
- F1Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
- F2Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12.